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Biopharmaceutical innovation can improve quality assurance, manufacturing capacity & process efficiency. 
However global regulatory trends are a barrier to continuous improvement and acceleration only exacerbates 
product development.  
 
While several recent draft guidelines & initiatives1-3 portend to enable innovation, in practice, regulatory 
expectations reflect increasingly punitive rather than incentive-based opportunities: 
 
•        Redundant downstream justification for upstream changes, i.e., stability 
 
•        Submission of GMP/supply chain information for review 
 
•        Misaligned regulatory review & inspection  
 
•        Global regulatory divergence – RSMs, viral clearance, PACs 
 
This presentation describes manufacturing innovations in the context of increasing regulatory demands & under 
accelerated development timelines. 
 
 1Assay Development & Validation for Immunogenicity Testing of Therapeutic Protein Products, Draft Guidance 
for Industry, FDA/CDER, CBER & CDRH, April 2016. 
 
2Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base, 
Draft Guidance for Industry, FDA/CDER, December 2015. 
 
3Established Conditions:  Reportable CMC Changes for Drug and Biologic Products, Draft Guidance for 
Industry, FDA/CDER & CBER, May 2015. 
 
